Effects of simvastatin on the mevalonate pathway and cell wall integrity of Staphylococcus aureus

被引:0
作者
Cortes, Iago Torres [1 ]
Silva, Katia de Padua [2 ]
Cogo-Mueller, Karina [1 ,2 ]
机构
[1] Univ Estadual Campinas, Fac Odontol Piracicaba, Ave Limeira 901, BR-13414903 Piracicaba, SP, Brazil
[2] Univ Estadual Campinas, Fac Ciencias Farmaceut, Rua Candido Portinari 200,Cidade Univ, BR-13083871 Campinas, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
simvastatin; Staphylococcus aureus; drug repositioning; antibacterial agents; gene expression; mevalonate pathway; HMG-COA REDUCTASE; ANTIBIOTIC-RESISTANCE; 2-COMPONENT SYSTEM; BIOSYNTHESIS; VRASR; METABOLISM; SEQUENCE; GENE; TRANSCRIPTION; PHARMACOLOGY;
D O I
10.1093/jambio/lxaf012
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Aims To investigate the effects of simvastatin as an antimicrobial, considering its influence on the mevalonate pathway and the bacterial cell wall of S. aureus.Methods and Results S. aureus ATCC 29213 and 33591 were exposed to simvastatin in the presence of exogenous mevalonate to determine whether mevalonate could reverse the inhibition. S. aureus was also treated with simvastatin and gene expression analysis assays were performed to evaluate genes associated with the mevalonate pathway (mvaA, mvaS, mvaK1, and mvaK2), peptidoglycan synthesis (uppS, uppP, and murG), and cell wall stress (vraX, sgtB, and tcaA). Transmission electron microscopy was used to identify the presence of morphological changes. The data were compared using two-way ANOVA and Bonferroni post-test, or the Mann-Whitney test. Addition of exogenous mevalonate was able to partially or completely reverse the inhibition caused by simvastatin. A significant increase of the vraX gene and a reduction of the mvaA gene were observed, together with changes in bacterial morphology.Conclusion Simvastatin can exert its antimicrobial effect by means of changes in the cell wall associated with the mevalonate pathway.
引用
收藏
页数:12
相关论文
共 67 条
  • [1] [Anonymous], 2008, GUIDE PERFORMING REL
  • [2] The Mevalonate Pathway of Staphylococcus aureus
    Balibar, Carl J.
    Shen, Xiaoyu
    Tao, Jianshi
    [J]. JOURNAL OF BACTERIOLOGY, 2009, 191 (03) : 851 - 861
  • [3] A close-up view of the VraSR two-component system - A mediator of staphylococcus aureus response to cell wall damage
    Belcheva, Antoaneta
    Golemi-Kotra, Dasantila
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (18) : 12354 - 12364
  • [4] Roles of DNA Sequence and Sigma A Factor in Transcription of the vraSR Operon
    Belcheva, Antoaneta
    Verma, Vidhu
    Korenevsky, Artyom
    Fridman, Michael
    Kumar, Krishan
    Golemi-Kotra, Dasantila
    [J]. JOURNAL OF BACTERIOLOGY, 2012, 194 (01) : 61 - 71
  • [5] Studies on the Antibacterial Effects of Statins - In Vitro and In Vivo
    Bergman, Peter
    Linde, Charlotte
    Putsep, Katrin
    Pohanka, Anton
    Normark, Staffan
    Henriques-Normark, Birgitta
    Andersson, Jan
    Bjorkhem-Bergman, Linda
    [J]. PLOS ONE, 2011, 6 (08):
  • [6] The nature of Staphylococcus aureus MurA and MurZ and approaches for detection of peptidoglycan biosynthesis inhibitors
    Blake, Katy L.
    O'Neill, Alex J.
    Mengin-Lecreulx, Dominique
    Henderson, Peter J. F.
    Bostock, Julieanne M.
    Dunsmore, Colin J.
    Simmons, Katie J.
    Fishwick, Colin W. G.
    Leeds, Jennifer A.
    Chopra, Ian
    [J]. MOLECULAR MICROBIOLOGY, 2009, 72 (02) : 335 - 343
  • [7] Sequence comparisons reveal two classes of 3-hydroxy-3-methylglutaryl coenzyme A reductase
    Bochar, DA
    Stauffacher, CV
    Rodwell, VW
    [J]. MOLECULAR GENETICS AND METABOLISM, 1999, 66 (02) : 122 - 127
  • [8] Epidemiology of methicillin-resistant Staphylococcus aureus
    Boucher, Helen W.
    Corey, G. Ralph
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 46 : S344 - S349
  • [9] BROWN MS, 1980, J LIPID RES, V21, P505
  • [10] Bugg Timothy D. H., 2006, Infectious Disorders - Drug Targets, V6, P85, DOI 10.2174/187152606784112128